Unknown Manufacturer
CSL324 is a fully human anti-G-CSFR antibody shown to have the ability to control G-CSF-mediated neutrophilia in cynomolgus macaques. It has potential applications in various inflammatory conditions such as cystic fibrosis, inflammatory bowel disease, rheumatoid arthritis, and vasculitis.
CSL324 is a fully human anti-G-CSFR antibody shown to have the ability to control G-CSF-mediated neutrophilia in cynomolgus macaques. It has potential applications in various inflammatory conditions such as cystic fibrosis, inflammatory bowel disease, rheumatoid arthritis, and vasculitis.
CSL324 binds to G-CSFR, which has been shown to neutralize the activity of G-CSF. Thus, this antibody is hypothesized to reduce G-CSF-driven mobilization and recruitment, which then, in turn, will aid in inflammation reduction. CSL324 also inhibits the G-CSF-mediated expression of CXCR1 and CXCR2 on neutrophils. Currently, it is being investigated against inflammation and COVID-19.
One entry per invention. Patent families filed in the US, EP, WO and CN offices.
